Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 10/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.37 |
| ▸ | F3 | P13726 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22805376 | 0.81 | PDE2A (0.41) | PDE2AGAAKMT2AMEN1PI4KA | |
| SCHEMBL10307718 | 0.80 | PDE2A (0.43) | PDE2AGAAKMT2AMEN1PI4KA | |
| SCHEMBL30095667 | 0.79 | PDE2A (0.60) | PDE2AGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL31391465 | 0.78 | PDE2A (0.42) | PDE2AGAAKMT2AMEN1PI4KA | |
| SCHEMBL25746365 | 0.78 | PDE2A (0.42) | PDE2AGAAKMT2AMEN1PI4KA | |
| SCHEMBL19117462 | 0.78 | PDE2A (0.42) | PDE2AGAAKMT2AMEN1PI4KA | |
| SCHEMBL4409891 | 0.77 | PI4KA (0.55) | PDE2AKMT2AMEN1PI4KAPI4K2B | |
| SCHEMBL18343699 | 0.77 | PDE2A (0.49) | PDE2AGAAKMT2AMEN1PI4KA | |
| SCHEMBL30935932 | 0.76 | PDE2A (0.40) | PDE2AGAAKMT2AMEN1PI4KA | |
| SCHEMBL20674220 | 0.76 | PDE2A (0.40) | PDE2AGAAKMT2AMEN1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603511-B1 | 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-15 | — | — | EP | disclosed |
| US-9079905-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-8912201-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20130040971-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20120202829-A1 | 6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-09 | — | — | US | disclosed |
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040971-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE2A | PDE2A 3/4885GAA 409/4885KMT2A 3270/4885 |
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | CNR1, CNR2, CHRM5 | PDE2A 551/4885GAA 2258/4885KMT2A 2095/4885 |
| US-20120202829-A1 | 6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders | PDE9A, PDE7A, PDE2A | PDE2A 3/4885GAA 512/4885KMT2A 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.